NCT04744532Source recordAI-normalized
Phase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
The Phase 1/2 study of bosutinib in ALS patients, sponsored by Kyoto University, represents a potential breakthrough in the treatment of amyotrophic lateral sclerosis (ALS), particularly for patients with SOD1 mutations. The market for ALS therapies is growing, with limited options currently available, primarily edaravone and riluzole. The successful development of bosutinib could position it as a competitive alternative, especially if it demonstrates significant efficacy and safety in the trial. The collaboration with multiple universities and Pfizer enhances credibility and may facilitate broader clinical acceptance and potential commercialization. However, the competitive landscape remains challenging, with ongoing research into novel therapies for ALS, necessitating diligent monitoring of trial outcomes and competitor developments.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
Sponsor: Kyoto University
Source URL: ClinicalTrials.gov
Source updated: Mar 08, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
Target normalized: Bosutinib, a dual Src/Abl inhibitor, targeting pathways involved in neuroinflammation and neuronal survival.
NCT05287958Source recordAI-normalized
A Pilot Study on the Technical Feasibility of an Electrical Impedance Tomography Device for Quantitative Pulmonary Function Testing in ALS Patients
This pilot study, sponsored by Beth Israel Deaconess Medical Center, aims to evaluate the technical feasibility of an Electrical Impedance Tomography (EIT) device for noninvasive pulmonary function testing in patients with Amyotrophic Lateral Sclerosis (ALS). The study's completion indicates a potential advancement in pulmonary monitoring technologies, particularly for ALS patients who often experience respiratory complications. The market for respiratory monitoring devices is growing, driven by increasing prevalence of chronic respiratory diseases and the need for innovative, noninvasive diagnostic tools. Competitive implications include the potential for EIT to differentiate itself from traditional pulmonary function tests (PFTs) by offering real-time imaging and assessment. Diligence considerations should focus on regulatory pathways, reimbursement strategies, and the integration of EIT into existing clinical workflows.
AI analysis
Indication: ALS
Modality: medical device
Target: Electrical Impedance Tomography (EIT) for pulmonary function monitoring
Sponsor: Beth Israel Deaconess Medical Center
Source URL: ClinicalTrials.gov
Source updated: Apr 16, 2024
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: ALS
View original source fields
Condition raw: ALS
Condition normalized: ALS
Modality raw: medical device
Modality normalized: medical device
Target raw: Electrical Impedance Tomography (EIT) for pulmonary function monitoring
Target normalized: Electrical Impedance Tomography (EIT) for pulmonary function monitoring
NCT01605006Source recordAI-normalized
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
The NeuRx Diaphragm Pacing System (DPS) is positioned as a therapeutic intervention for patients with Amyotrophic Lateral Sclerosis (ALS) experiencing chronic hypoventilation. With a target enrollment of 60 participants, the study aims to assess the safety and probable benefits of the device over a two-year follow-up period. Given the increasing prevalence of ALS and the limited treatment options available, the NeuRx DPS addresses a significant unmet medical need in respiratory management for ALS patients. The competitive landscape includes traditional mechanical ventilation and other emerging therapies, but the NeuRx DPS offers a unique, less invasive alternative that could enhance patient quality of life. The successful demonstration of safety and efficacy could facilitate broader adoption and potential reimbursement pathways, enhancing market penetration. Diligence considerations should focus on regulatory compliance, post-market surveillance, and the evolving landscape of ALS treatment options.
AI analysis
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: medical device
Target: Diaphragm muscle stimulation via phrenic nerve activation.
Sponsor: Synapse Biomedical
Source URL: ClinicalTrials.gov
Source updated: Mar 27, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: medical device
Modality normalized: medical device
Target raw: Diaphragm muscle stimulation via phrenic nerve activation.
Target normalized: Diaphragm muscle stimulation via phrenic nerve activation.
NCT01536249Source recordAI-normalized
An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers
Knopp Biosciences' study on dexpramipexole, an investigational drug for ALS, aims to elucidate the pharmacokinetic interactions with cimetidine. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes could position dexpramipexole favorably in a niche market. The study's completion in 2012 suggests that data may be available for further development or partnership opportunities. However, the competitive landscape includes other emerging therapies for ALS, necessitating a thorough analysis of dexpramipexole's unique value proposition and potential market differentiation.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
Sponsor: Knopp Biosciences
Source URL: ClinicalTrials.gov
Source updated: Nov 25, 2014
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
Target normalized: Dexpramipexole targets the glutamate transporter EAAT2, which is implicated in neuroprotection and modulation of excitotoxicity, particularly relevant in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
NCT07080801Source recordAI-normalized
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes. In Asia, mutations in the FUS gene are relatively common among early-onset familial ALS patients. Reducing the levels of toxic FUS protein may be an effective therapeutic approach for such ALS patients without causing side effects. RAG-21 is a small interfering ribonucleic acid (siRNA) with a molecular weight of 20 kDa. Through the RNA interference mechanism, it targets the FUS gene, recognizes the corresponding mRNA, and mediates its degradation, thereby downregulating FUS gene expression and reducing toxic FUS protein levels. Accordingly, this project plans to conduct a single-center, dose-escalation clinical study aimed at evaluating the safety, tolerability, and pharmacokinetics of intrathecal bolus administration of RAG-21 in ALS patients carrying FUS gene mutations.
AI analysis
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: small molecule
Target: RAG-21
Sponsor: Beijing Tiantan Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: RAG-21
Target normalized: RAG-21
NCT02682030Source recordAI-normalized
Utilization of Pulmonary Clearance Devices in Amyotrophic Lateral Sclerosis
The investigator is examining the use of one airway clearance medical device compared to the use of two airway clearance medical devices together in patients with amyotrophic lateral sclerosis (ALS). More specifically, the investigator wants to know how effective the use of either a mechanical High Frequency Chest Compression (HFCC) device is on its own or the use of both a mechanical High Frequency Chest Compression (HFCC) device and Cough Assist together to maintain a healthy airway and clear secretions. The first device is a passive form of mechanical High Frequency Chest Compression (HFCC), which was designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area. The second device, called a Cough Assist, aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing. This study will enroll up to 20 people in total at CSMC.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: medical device
Target: High Frequency Chest Compression Device (HFCC), Cough Assist
Sponsor: Cedars-Sinai Medical Center
Source URL: ClinicalTrials.gov
Source updated: Aug 25, 2020
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: medical device
Modality normalized: medical device
Target raw: High Frequency Chest Compression Device (HFCC), Cough Assist
Target normalized: High Frequency Chest Compression Device (HFCC), Cough Assist
NCT03487263Source recordAI-normalized
A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. Safety, tolerability, immunogenicity, and PK/PD will be measured. To evaluate feasibility of the endpoints, additional endpoints of ALSFRS-R, respiratory function tests, disease biomarkers and patient-reported outcomes will be measured.
AI analysis
Indication: Motor Neuron Disease
Modality: monoclonal antibody
Target: IC14
Sponsor: Implicit Bioscience
Source URL: ClinicalTrials.gov
Source updated: Aug 20, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Motor Neuron Disease
View original source fields
Condition raw: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Condition normalized: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: IC14
Target normalized: IC14
NCT06889857Source recordAI-normalized
Safety and Efficacy of Intravenous Administration of SHED-CM for ALS
This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: The study drug is SHED-CM manufactured by U-Factor
Sponsor: Hitonowa Medical
Source URL: ClinicalTrials.gov
Source updated: Sep 15, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: The study drug is SHED-CM manufactured by U-Factor
Target normalized: The study drug is SHED-CM manufactured by U-Factor
NCT00965497Source recordAI-normalized
An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis
Escitalopram (Lexapro) is being evaluated for its efficacy in treating major depressive disorder in patients with comorbid Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Given the increasing recognition of mental health issues in chronic neurological conditions, this study addresses an unmet need in the market. The potential to expand Lexapro's indications could enhance its market position against competitors in the antidepressant space, particularly those targeting similar patient populations. The results may influence prescribing practices and reimbursement policies, thereby impacting market access and commercial strategy for the product.
AI analysis
Indication: Major Depression
Modality: small molecule
Target: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.
Sponsor: University of South Carolina
Source URL: ClinicalTrials.gov
Source updated: May 01, 2019
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Condition normalized: Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.
Target normalized: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.
NCT00397423Source recordAI-normalized
Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response
Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response is a PHASE2 clinical asset sponsored by Peking University in Amyotrophic Lateral Sclerosis. SEO and diligence focus: Granulocyte Colony Stimulating Factor, NS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: Granulocyte Colony Stimulating Factor, NS
Sponsor: Peking University
Source URL: ClinicalTrials.gov
Source updated: Nov 28, 2007
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Granulocyte Colony Stimulating Factor, NS
Target normalized: Granulocyte Colony Stimulating Factor, NS
NCT07298486Source recordAI-normalized
Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS: A Pilot Study
Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS: A Pilot Study is a NA clinical asset sponsored by Nova Southeastern University in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: Robotic Glove Use, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: medical device
Target: Robotic Glove Use
Sponsor: Nova Southeastern University
Source URL: ClinicalTrials.gov
Source updated: Feb 25, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: ALS
Modality normalized: medical device
Target raw: Robotic Glove Use
Target normalized: Robotic Glove Use
NCT04931862Source recordAI-normalized
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) is a PHASE1 clinical asset sponsored by Wave Life Sciences Ltd. in ALS, FTD. SEO and diligence focus: WVE-004, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: ALS
Modality: small molecule
Target: WVE-004, Placebo
Sponsor: Wave Life Sciences Ltd.
Source URL: ClinicalTrials.gov
Source updated: Oct 23, 2023
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: ALS
View original source fields
Condition raw: ALS
Condition normalized: ALS
Modality raw: antisense oligonucleotide
Modality normalized: small molecule
Target raw: WVE-004, Placebo
Target normalized: WVE-004, Placebo